Value by Design: Strategic Execution Architecture in Clinical-Stage Biotech

Running four Phase II oncology studies in parallel exposed a fundamental truth: in clinical-stage biotech, execution failure is not a delivery problem — it is a value problem. This session draws on Ryvu’s experience building an internal clinical execution unit from scratch, covering the strategic decisions behind insourcing key functions, building a CEE-anchored site network, and delivering ASH 2025 data on time. Attendees will leave with a practical framework for thinking about clinical program architecture as a value inflection decision, not an operational one.

The Wearable Sensor CRO: A New Model for Implementing Digital Measures that Must Withstand Regulatory Scrutiny

  • How well‑designed digital measures deliver measurable ROI in clinical trials by reducing missing data, improving statistical power, accelerating timelines, and preventing costly trial rework or failure.
  • How an end‑to‑end Wearable Sensor CRO delivery model integrates scientific strategy, operational oversight, and analytics to consistently produce regulatory‑ready datasets.
  • Real‑world case examples showing how proactive compliance monitoring and fit‑for‑purpose algorithms dramatically improve data completeness and statistical power.
  • The critical role of disease‑specific digital endpoint design versus off‑the‑shelf wearable algorithms in capturing meaningful treatment effects.
  • Practical guidance for clinical operations and outsourcing teams on reducing sponsor burden while scaling wearable technologies across global trials.